Moderna mRNA-1010 flu vaccine produces broader multi-strain immunity, FDA decision expected August
Adults over 50 may soon get a flu shot covering far more strains than today's. Moderna's mRNA-1010 $MRNA bound flu strains across decades of evolution for six months and cut illness risk 26.6% vs the standard shot in older adults. FDA decision due in August. Per Nature Immunology
A next-generation flu shot moved closer to approval this summer, and the target group is the one that needs it most: older adults. In findings published in Nature Immunology, Moderna's investigational mRNA-1010 vaccine ($MRNA) prompted antibodies that recognized a wide range of influenza strains spanning decades of the virus's evolution. That breadth held from about four weeks after vaccination through the six-month mark, whereas antibodies from recipients of a standard seasonal shot bound to far fewer divergent strains. The clinical payoff showed up separately: in a phase 3 trial, mRNA-1010 reduced the risk of flu illness by 26.6% more than a standard vaccine in older adults, and an FDA advisory committee voted unanimously that it is safe and effective for people aged 50 and older. A final FDA decision is expected in August. Why it matters beyond one product: mRNA manufacturing can be reprogrammed for new strains in weeks rather than the months egg-based production needs. In a bad-match season, that speed is the difference between a vaccine that tracks the circulating virus and one that trails it. For people over 50, who carry the heaviest flu burden, a broader and faster-updating shot is a meaningful shift. According to Nature Immunology and WashU Medicine.